InvestorsHub Logo
Followers 9
Posts 1766
Boards Moderated 0
Alias Born 01/26/2015

Re: None

Friday, 03/04/2022 11:28:23 AM

Friday, March 04, 2022 11:28:23 AM

Post# of 1616
Simply a quote: "Anthony Dudzinski, COO, stated, "To date, participants have completed the initial screening process, meeting our extensive inclusion/exclusion criteria, and treatments and follow up assessments have begun. We believe that ATCELL™ for PCS is a ‘first of its kind' autologous cellular therapy protocol subject to FDA clinical studies that has the ability to become an industry standard to treat patients suffering from the effects of post-concussion syndrome resulting from mild traumatic brain (mTBI) injuries. Treatments will become available upon completion of clinical studies and FDA marketing approval.""

https://finance.yahoo.com/news/american-cryostem-announces-patient-treatment-110000832.html
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.